Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00598780 · ClinicalTrials.gov registry record
Evaluation of Safety of Levocetirizine in Routine Clinical Practice-non- Interventional Study
A clinical trial of Rhinitis Allergic, Persistent, sponsored by UCB Pharma.
- Completed
- Registry status
- 7,870
- Enrollment target
- 1
- Study location
NCT00598780 is a study of Rhinitis Allergic, Persistent that has completed, run by UCB Pharma. The registered enrollment target is 7,870 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00598780, a study of Rhinitis Allergic, Persistent, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- 7,870 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate over a period of 6 months the safety and the treatment satisfaction of newly prescribed levocetirizine in patients of age ≥ 2 years with persistent allergic rhinitis.
Conditions Studied
Study Locations (1)
Georgia
- UCB Pharma - Smyrna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,870 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00598780
The ClinicalTrials.gov registry entry for NCT00598780 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7,870 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rhinitis Allergic, Persistent appearing as the primary indexed condition, and to 0 interventions.
NCT00598780 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT00598780 about?
NCT00598780 is a clinical study titled "Evaluation of Safety of Levocetirizine in Routine Clinical Practice-non- Interventional Study". To evaluate over a period of 6 months the safety and the treatment satisfaction of newly prescribed levocetirizine in patients of age ≥ 2 years with persistent allergic rhinitis.
What is the current status of trial NCT00598780?
This trial is currently completed. The enrollment target is 7,870 participants. The study started on 2007-09. Estimated completion is 2008-09.
What conditions does trial NCT00598780 study?
This clinical trial studies the following conditions: Rhinitis Allergic, Persistent.
Who is sponsoring clinical trial NCT00598780?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00598780 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.